'Booming' China Pharma R&D Reaches New Peak
Landmark As Two Firms Enter Top 25
China has emerged as a major new force in global pharma R&D amid a "boom" in activity, with not one but two of its companies entering the top 25 by pipeline size for the first time.
You may also be interested in...
While China approved a record number of innovative oncology drugs in 2021, the correlation between their novel mechanisms of action or targeted indication and clinical benefit is not statistically insignificant, a well-known researcher claims in a new report.
Pharma’s R&D engine has been firing on all cylinders in the past year – pipeline growth in 2021 stood at nearly twice that for the previous year, pushing the number of products under active development over 20,000 for the first time.
China’s largest innovative domestic drug maker will only take global those products that play into its strengths, chairman Piaoyang Sun declares.